Endometrial Curettage When and for Who
Aslıhan Duman,
Ferah Tuncel Daloğlu,
Yeliz Arman Karakaya,
Aysun Aras
Issue:
Volume 3, Issue 2, March 2015
Pages:
17-21
Received:
12 February 2015
Accepted:
27 February 2015
Published:
9 March 2015
Abstract: In this study, the histopathological diagnoses pertaining to curettage material and the clinical necessity and results of endometrial curettagein age groups of patients in our region who had curettage due to abnormal uterine bleeding were studied. Thehistopathological diagnoses of patients with the above-mentioned criteria were scanned, excluding those related to pregnancy. 409 cases were re-examined and evaluated by a group consisting of three pathologists. Diagnoses were classified into 10 different groups. According to this classification system, out of the total number of cases, 100 were defined as endometrial polyp (24.4%), 72 cases as secretory endometrium (17.6%), 59 cases as proliferative endometrium (14.4%), 51 cases as stromal/glandular degeneration (12.5%), 32 cases as irregular proliferation (7.8%), 26 cases as insufficient (6.4%), 22 cases as chronic endometritis (5.6%), 18 cases as decidualization (4.4%), 17 cases as endometrial hyperplasia (complex atypical)/ adenocarcinoma (4.2%), and 12 cases as others (inactive, atrophic, basal and menstrual endometrium) (2.9%). The average age of the 409 cases was 44.8±7.8. Upon evaluation of curettage due to abnormal uterine bleeding in the approximate 3 year period in our region, and taking into consideration the age distribution, it was observed that the clinical pre-diagnoses of patients especially with endometrial polyps and precancerous lesions were coherent with the corresponding histopathological diagnoses.
Abstract: In this study, the histopathological diagnoses pertaining to curettage material and the clinical necessity and results of endometrial curettagein age groups of patients in our region who had curettage due to abnormal uterine bleeding were studied. Thehistopathological diagnoses of patients with the above-mentioned criteria were scanned, excluding t...
Show More
A Standardized Plant Extract Containing a Target Compound is Acceptable as a Potent Therapeutic Entity: Relevance to BEC and Solamargine, a Topical Clinical Formulation CuradermBEC5
Aruba Cham,
Kai Cham,
Tania Chase,
Bill Cham
Issue:
Volume 3, Issue 2, March 2015
Pages:
22-27
Received:
26 February 2015
Accepted:
19 March 2015
Published:
24 March 2015
Abstract: New approaches to curb developmental and end-stage production expenses, whilst generating a safe and effective treatment for cancer, resulting in lower cost for the patient and healthcare system, are warranted. A bioassay-guided fractionation of a Solanum plant, S. sodomaeum, to a standardized extract can be classified as a new drug. It is shown that a specific standardized plant extract, BEC, containing a given concentration of a target efficacious and safe compound, solamargine, is an acceptable anticancer and less costly chemotherapeutic reality.
Abstract: New approaches to curb developmental and end-stage production expenses, whilst generating a safe and effective treatment for cancer, resulting in lower cost for the patient and healthcare system, are warranted. A bioassay-guided fractionation of a Solanum plant, S. sodomaeum, to a standardized extract can be classified as a new drug. It is shown th...
Show More
